SCHEMBL975805

SCHEMBL975805

CS(=O)(=O)N(c1cccc(C(=O)NCC(N)=O)c1)C1CN(C(c2ccc(Cl)cc2)c2ccc(Cl)cc2)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA2D1 P54289 1/20 0.38
CACNA1B Q00975 1/20 0.38
CACNB1 Q02641 1/20 0.38
CACNA1C Q13936 1/20 0.38
F2 P00734 2/20 0.36
CCR2 P41597 8/20 0.36
ALOX5 P09917 1/20 0.36
EPHX2 P34913 1/20 0.36
KMT2A Q03164 3/20 0.36
DRD2 P14416 1/20 0.36
DRD3 P35462 1/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MEN1 O00255 2/20 0.35
MAPT P10636 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL979308 0.92 CACNA2D1 (0.41) CACNA2D1CACNA1BCACNB1CACNA1CF2
SCHEMBL977615 0.91 ALOX5 (0.39) CACNA2D1CACNA1BCACNB1CACNA1CF2
SCHEMBL977202 0.90 CCR2 (0.39) CACNA2D1CACNA1BCACNB1CACNA1CCCR2
SCHEMBL3659285 0.90 ALOX5 (0.40) CACNA2D1CACNA1BCACNB1CACNA1CF2
SCHEMBL3661019 0.89 MEN1 (0.38) CACNA2D1CACNA1BCACNB1CACNA1CF2
SCHEMBL975802 0.89 F2 (0.48) CACNA2D1CACNA1BCACNB1CACNA1CF2
SCHEMBL3408675 0.89 DRD2 (0.40) CACNA2D1CACNA1BCACNB1CACNA1CF2
SCHEMBL975469 0.88 PTPRC (0.41) CACNA2D1CACNA1BCACNB1CACNA1CF2
SCHEMBL976717 0.88 F2 (0.39) CACNA2D1CACNA1BCACNB1CACNA1CF2
Hydrochloric Acid SCHEMBL6519318 0.88 DRD2 (0.39) CACNA2D1CACNA1BCACNB1CACNA1CF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2234966-B1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY SANOFI SA (FR) 2013-09-11 EP claimed
US-8445478-B2 Azetidine derivatives, their preparation and their application in therapy SANOFI (FR) 2013-05-21 US claimed
US-20110009377-A1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY SANOFI-AVENTIS (FR) 2011-01-13 US claimed
US-20130237513-A1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY SANOFI (FR) 2013-09-12 US disclosed
EP-2234966-B1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY SANOFI SA (FR) 2013-09-11 EP disclosed
US-8445478-B2 Azetidine derivatives, their preparation and their application in therapy SANOFI (FR) 2013-05-21 US disclosed
US-20110009377-A1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY SANOFI-AVENTIS (FR) 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237513-A1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY QDPR, AZI2, ADRA1B CACNA2D1 2643/4885CACNA1B 1231/4885CACNB1 2792/4885
US-20110009377-A1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY QDPR, AZI2, ADRA1B CACNA2D1 2643/4885CACNA1B 1231/4885CACNB1 2792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.